Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

7.805 -0.085 (-1.08%)
Streaming Delayed Price Updated: 3:20 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 178,967
Open 7.835
Bid (Size) 7.800 (2)
Ask (Size) 7.810 (4)
Prev. Close 7.890
Today's Range 7.565 - 7.855
52wk Range 6.850 - 24.99
Shares Outstanding 199,873,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-37.0%
-37.0%
1 Month
-6.8%
-6.8%
3 Month
-14.7%
-14.7%
6 Month
-36.1%
-36.1%
1 Year
-66.3%
-66.3%

More News

Read More
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Via Benzinga
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
The current price of Cullinan Therapeutics, Inc. - Common Stock is 7.805
When was Cullinan Therapeutics, Inc. - Common Stock last traded?
The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 05/23/25 03:20 PM ET
What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 1.56B
How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
Cullinan Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.